Fortress Biotech (FBIO) Interest Coverage Ratio: History & Chart

Fortress Biotech, Inc.(FBIO)

Biotechnology · Bay Harbor Islands, FL

$2.05-0.04 (-1.91%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

FBIO Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-8.06x

INTEREST COVERAGE RATIO AVG TTM

-6.46x

INTEREST COVERAGE RATIO AVG 3Y

-8.55x

INTEREST COVERAGE RATIO AVG 5Y

-10.71x

INTEREST COVERAGE RATIO AVG 10Y

-10.47x

INTEREST COVERAGE RATIO AVG 15Y

-15.04x

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-24.83%

CURRENT VS 3Y AVG

+5.76%

CURRENT VS 5Y AVG

+24.73%

CURRENT VS 10Y AVG

+23.02%

CURRENT VS 15Y AVG

+46.42%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-6.38x

median of 528 covered companies

CURRENT VS SECTOR MEDIAN

-26.43%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Fortress Biotech, Inc. (FBIO)	$68.10M	-8.06x	-6.46x	-8.55x	-10.71x
iBio, Inc. (IBIO)vs ›	$67.52M	-663.04x	N/A	N/A	N/A
Spero Therapeutics, Inc. (SPRO)vs ›	$68.90M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.61M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	-14.86x	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.86M	-21.57x	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	-632.78x	N/A	N/A	N/A
Tiziana Life Sciences Ltd (TLSA)vs ›	$70.63M	-1174.00x	N/A	N/A	N/A
Gain Therapeutics, Inc. (GANX)vs ›	$71.23M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$64.18M	-66.90x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Fortress Biotech, Inc. (FBIO)

$68.10M

-8.06x

-6.46x

-8.55x

-10.71x

iBio, Inc. (IBIO)vs ›

$67.52M

-663.04x

N/A

Spero Therapeutics, Inc. (SPRO)vs ›

$68.90M

N/A

Champions Oncology, Inc. (CSBR)vs ›

$69.61M

N/A

Gossamer Bio, Inc. (GOSS)vs ›

$65.87M

-14.86x

N/A

Cingulate Inc. (CING)vs ›

$65.86M

-21.57x

N/A

XBiotech Inc. (XBIT)vs ›

$65.85M

-632.78x

N/A

Tiziana Life Sciences Ltd (TLSA)vs ›

$70.63M

-1174.00x

N/A

Gain Therapeutics, Inc. (GANX)vs ›

$71.23M

N/A

Alps Group Inc (ALPS)vs ›

$64.18M

-66.90x

N/A

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The interest coverage ratio for FBIO stock is -8.06x.

Is Fortress Biotech, Inc.'s interest coverage ratio high or low?

The interest coverage ratio of -8.06x is 25% above its 5-year average of -10.71x, around the middle of its 5-year range (-20.11x–-2.30x).

What is the TTM average interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The TTM average interest coverage ratio for FBIO stock is -6.46x.

What is the 3Y average interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The 3Y average interest coverage ratio for FBIO stock is -8.55x.

What is the 5Y average interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The 5Y average interest coverage ratio for FBIO stock is -10.71x.

What is the 10Y average interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The 10Y average interest coverage ratio for FBIO stock is -10.47x.

What is the 15Y average interest coverage ratio for Fortress Biotech, Inc. (FBIO)?

The 15Y average interest coverage ratio for FBIO stock is -15.04x.

DATE	INTEREST COVERAGE RATIO
2026-06-30	-6.78x
2026-03-31	-2.30x
2025-12-31	-2.80x
2025-09-30	-2.82x
2025-06-30	-17.59x
2025-03-31	-8.89x
2024-12-31	-10.54x
2024-09-30	-3.56x
2024-06-30	-13.10x
2024-03-31	-14.05x
2023-12-31	-9.52x
2023-09-30	-5.43x
2023-06-30	-13.81x
2023-03-31	-13.70x
2022-12-31	-11.51x
2022-09-30	-14.95x
2022-06-30	-16.15x
2022-03-31	-20.11x
2021-12-31	-10.48x
2021-09-30	-11.23x
2021-06-30	-15.53x
2021-03-31	-13.71x
2020-12-31	-11.13x
2020-09-30	-3.31x
2020-06-30	-8.30x
2020-03-31	-6.89x
2019-12-31	-9.78x
2019-09-30	-7.11x
2019-06-30	-8.14x
2019-03-31	-13.21x
2018-12-31	-9.02x
2018-09-30	-10.62x
2018-06-30	-9.81x
2018-03-31	-14.22x
2017-12-31	-49.53x
2017-09-30	-10.13x
2017-06-30	-16.81x
2017-03-31	-25.04x
2016-12-31	-10.39x
2016-09-30	-23.58x
2016-06-30	-28.61x
2016-03-31	-60.12x
2015-12-31	-28.00x
2015-09-30	-51.63x
2015-06-30	-22.05x
2015-03-31	-36.47x
2014-12-31	-37.58x
2014-09-30	-35.92x
2014-06-30	-40.03x
2014-03-31	-6.81x
2013-12-31	-21.21x
2013-09-30	-15.22x
2013-06-30	-21.22x
2013-03-31	-17.77x
2012-12-31	-18.48x
2012-09-30	-31.86x
2012-06-30	-340.26x
2012-03-31	-346.37x
2011-12-31	-275.37x
2011-09-30	-185.84x
2011-06-30	-196.63x
2011-03-31	-1326.18x
2010-12-31	10.21x
2010-09-30	-33.58x

DATE

INTEREST COVERAGE RATIO

2026-06-30

-6.78x

2026-03-31

-2.30x

2025-12-31

-2.80x

2025-09-30

-2.82x

2025-06-30

-17.59x

2025-03-31

-8.89x

2024-12-31

-10.54x

2024-09-30

-3.56x

2024-06-30

-13.10x

2024-03-31

-14.05x

2023-12-31

-9.52x

2023-09-30

-5.43x

2023-06-30

-13.81x

2023-03-31

-13.70x

2022-12-31

-11.51x

2022-09-30

-14.95x

2022-06-30

-16.15x

2022-03-31

-20.11x

2021-12-31

-10.48x

2021-09-30

-11.23x

2021-06-30

-15.53x

2021-03-31

-13.71x

2020-12-31

-11.13x

2020-09-30

-3.31x

2020-06-30

-8.30x

2020-03-31

-6.89x

2019-12-31

-9.78x

2019-09-30

-7.11x

2019-06-30

-8.14x

2019-03-31

-13.21x

2018-12-31

-9.02x

2018-09-30

-10.62x

2018-06-30

-9.81x

2018-03-31

-14.22x

2017-12-31

-49.53x

2017-09-30

-10.13x

2017-06-30

-16.81x

2017-03-31

-25.04x

2016-12-31

-10.39x

2016-09-30

-23.58x

2016-06-30

-28.61x

2016-03-31

-60.12x

2015-12-31

-28.00x

2015-09-30

-51.63x

2015-06-30

-22.05x

2015-03-31

-36.47x

2014-12-31

-37.58x

2014-09-30

-35.92x

2014-06-30

-40.03x

2014-03-31

-6.81x

2013-12-31

-21.21x

2013-09-30

-15.22x

2013-06-30

-21.22x

2013-03-31

-17.77x

2012-12-31

-18.48x

2012-09-30

-31.86x

2012-06-30

-340.26x

2012-03-31

-346.37x

2011-12-31

-275.37x

2011-09-30

-185.84x

2011-06-30

-196.63x

2011-03-31

-1326.18x

2010-12-31

10.21x

2010-09-30

-33.58x

Interest Coverage Ratio: -8.06x

FBIO Interest Coverage Ratio

FBIO Average Interest Coverage Ratio Chart

FBIO Current vs Average Interest Coverage Ratio Chart

FBIO Interest Coverage Ratio Metrics

FBIO Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

FBIO Interest Coverage Ratio History

Related Metrics